13-hydroxy-9-11-octadecadienoic-acid and Non-alcoholic-Fatty-Liver-Disease

13-hydroxy-9-11-octadecadienoic-acid has been researched along with Non-alcoholic-Fatty-Liver-Disease* in 2 studies

Other Studies

2 other study(ies) available for 13-hydroxy-9-11-octadecadienoic-acid and Non-alcoholic-Fatty-Liver-Disease

ArticleYear
Eicosanoids in Nonalcoholic Fatty Liver Disease (NAFLD) Progression. Do Serum Eicosanoids Profile Correspond with Liver Eicosanoids Content during NAFLD Development and Progression?
    Molecules (Basel, Switzerland), 2020, Apr-27, Volume: 25, Issue:9

    Nonalcoholic fatty liver disease (NAFLD) is becoming a major public health problem worldwide. The study aimed to evaluate the concentration of eicosanoids in serum and liver tissue during steatosis progression and to assess whether eicosanoid change scores may predict liver tissue remodeling. Thirty six eight-week-old male Sprague Dawley rats were enrolled and sacrificed at different stages of NAFLD. Eicosanoid concentrations, namely lipoxin A

    Topics: Animals; Biomarkers; Chromatography, Liquid; Dinoprostone; Disease Models, Animal; Disease Progression; Docosahexaenoic Acids; Eicosanoids; Eicosapentaenoic Acid; Hydroxyeicosatetraenoic Acids; Linoleic Acids; Lipoxins; Liver; Male; Non-alcoholic Fatty Liver Disease; Rats; Rats, Sprague-Dawley

2020
Apolipoprotein E4 allele is associated with substantial changes in the plasma lipids and hyaluronic acid content in patients with nonalcoholic fatty liver disease.
    Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2013, Volume: 64, Issue:6

    Fat may affect progression of liver damage in patients with non-alcoholic fatty liver disease (NAFLD). In this study we characterize the state of lipid metabolism in 22 patients with NAFLD and different Apo-E variants. Total concentration of plasma total fatty acids was quantified by gas chromatography, while their derivatives by liquid chromatography/tandem mass spectrometry (LC ESI MS/MS). The ratio of plasma saturated fatty acid to monounsaturated fatty acid increased, whereas the ratio of polyunsaturated fatty acids to saturated fatty acids was reduced in Apo-E4 carriers. Simultaneously, the levels of individual plasma linoleic, arachidonic, and alpha linolenic acids significantly increased in subjects with the Apo-E4 allele. The 15-lipoxygenase metabolite, 13-hydroxyoctadecadienoic acid, was significantly higher in Apo-E3 carriers (p<0.006). 5-oxo-6,8,11,14-eicosatetraenoic acid was significantly elevated in Apo-E4 carriers (p<0.009). A significant difference in hyaluronic acid concentration (p<0.0016) as well as predicted advanced fibrosis (using the BARD scoring system) was found in Apo-E4 carriers (p<0.01). We suggest that a distinct mechanism of fibrosis between Apo E alleles. In Apo-E4 carriers, an elevation in 5-oxo-6,8,11,14-eicosatetraenoic acid synthesis and fatty acid dysfunction may induce fibrosis, while an inflammatory process may be the main cause of fibrosis in Apo-E3 carriers.

    Topics: Adult; Aged; Alleles; Apolipoprotein E4; Arachidonic Acids; Fatty Acids; Fatty Liver; Female; Genotype; Humans; Hyaluronic Acid; Linoleic Acids; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease

2013